Abbott Laboratories (ABT) is a diversified global healthcare company spanning medical devices, diagnostics, nutrition, and established pharmaceuticals. Reviewing individual price targets attributed to specific firms and analysts, the range runs from about $140 (Mizuho's Neutral view) up to $162 (Barclays), with most targets clustered between roughly $142 and $154. Recent individual figures include RBC Capital at $147, Bernstein at $154 (raised from $150), Jefferies at $149, BTIG at $145, Wells Fargo at $146, Raymond James at $146, Piper Sandler at $150, and UBS at $154.
The arithmetic mean of these targets is roughly $148.6, which rounds to a $150 central target. This figure is an independently calculated average, not an official published consensus, and independent trackers have at times reported a slightly lower consensus of about $144 to $147. The broad agreement among analysts is an Outperform-to-Buy stance, with the divergence concentrated in magnitude: more cautious analysts cite diagnostics pricing pressure and uneven growth, while more bullish analysts emphasize medical-device momentum and long-term earnings power.
The stock recently traded near $100.50, well below its 52-week range of roughly $105 to $141 after a sustained 2026 decline. Reaching $150 from that level implies upside of approximately 49%, which is a very large required move. Notably, most of the analyst targets that anchor the $150 mean were set when the stock traded materially higher, so the gap between the current price and the average target partly reflects the share-price decline rather than a fresh round of upgrades.
Fundamentally, ABT has delivered mid-to-high single-digit revenue growth and maintains a diversified revenue base that includes high-demand categories such as glucose monitoring and structural heart devices. However, the company recently lowered its full-year comparable sales growth outlook, citing weakness in electrophysiology and diabetes. A path toward the target would likely require a stabilization and re-acceleration in those businesses, margin recovery, and renewed investor confidence in the valuation.
Several factors could support a recovery. Abbott's medical-device segment, including its FreeStyle Libre continuous glucose monitoring platform and structural heart products, remains a durable growth engine with accelerating procedure volumes. The company's diversified model provides multiple revenue streams that can offset weakness in any single unit. A contemplated acquisition in the diagnostics and cancer-screening space is viewed by many analysts as strategically attractive over the long term, and Abbott's track record as an established dividend payer offers a measure of downside support. Analysts who remain constructive also point to a valuation that has compressed during the selloff and to double-digit earnings-growth potential if margins stabilize.
The principal obstacle is the company's own guidance. The reduction in full-year comparable sales growth, driven by electrophysiology and diabetes, raises questions about near-term execution and the consistency of growth outside medical devices. Margin compression is another concern, as operating margins have slipped year over year. Integration risk and the premium valuation associated with a potential acquisition could also limit multiple expansion, while hospital budget pressures and reimbursement dynamics create macro uncertainty. Several price-target trims in recent quarters, even while ratings stayed positive, signal that investors may already be discounting a meaningful portion of the long-term growth story, leaving less room for error.
After the 2026 decline, the stock sits near a multi-year support zone around the $100 area, with chart-based support observed near $95 and again near $89. On the upside, a notable resistance level appears around $128, where earlier rallies have stalled. That $128 area is itself well below the $150 central target, meaning the stock would first need to clear a series of intermediate resistance levels before approaching the analyst average. The long-term structure has weakened, with the stock below its prior highs and trading near the lower end of its recent range.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts differ, and the targets referenced here were largely set before the most recent guidance revision. Investors should monitor upcoming earnings and guidance, particularly comparable sales growth in electrophysiology and diabetes, operating-margin trends, and any updates on the diagnostics acquisition. Analyst target revisions, hospital-procedure volume data, reimbursement decisions, and broader healthcare-sector sentiment will also matter. None of this provides a definitive forecast, but it frames the conditions under which the gap toward $150 could narrow or widen.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a name like Abbott that has experienced a sharp trend reversal, such signals can help traders track shifting momentum and volatility more efficiently. Traders can use the tool to discover new opportunities, monitor existing positions, and spot changing trends without manually scanning charts. Explore the AI Daily Buy/Sell Signals to see how automated analysis applies to your watchlist.
The $150 target represents the arithmetic mean of verified analyst price targets, not a guarantee or a prediction. With the stock near $100.50, the move required is roughly 49%, which is very large, and the average target may not fully reflect the company's recent guidance cut and the sharp 2026 share-price decline. The strongest supports are Abbott's diversified portfolio and medical-device franchise, while the principal obstacles are weakening electrophysiology and diabetes momentum, margin pressure, and potential acquisition-related risk. Analyst disagreement centers on the magnitude of upside rather than direction. Investors should watch upcoming guidance, segment-level growth, and analyst revisions to gauge whether conditions are improving toward the target or drifting further away.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ABT has been loosely correlated with MDT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ABT jumps, then MDT could also see price increases.
| Ticker / NAME | Correlation To ABT | 1D Price Change % |
|---|---|---|
| ABT | 100% | +1.14% |
| Health Services category (240 stocks) | 4% Poorly correlated | +0.07% |
| Medical/Nursing Services category (139 stocks) | 4% Poorly correlated | +0.27% |